Press release

DSM reports Q2 2016 results

Heerlen, NL, 02 Aug 2016 07:00 CEST


  • DSM reports a second consecutive strong quarter in 2016
  • Group net sales up at €1,994 million, with 5% organic growth, and EBITDA up 18%
  • Nutrition: organic sales growth of 9%, EBITDA up 14%
  • Materials: volumes up 5%, EBITDA up 10%
  • H1 Group ROCE: improved to 10.5% (H1 2015: 7.4%) driven by higher EBIT
  • Interim dividend of €0.55 per ordinary share
  • Outlook revised upward

Key figures and indicators (continuing operations)

in € million Q2 2016 Q2 2015 % change Volume Price/mix FX Other
Sales 1,994 1,965 1% 6% -1% -4% 0%
Nutrition 1,295 1,247 4% 7% 2% -5% 0%
Materials 640 664 -4% 5% -7% -2%  
EBITDA 328 279 18%        
Nutrition 237 208 14%        
Materials 117 106 10%        
ROCE (%) 10.5 7.4          

CEO statement

Feike Sijbesma, CEO/Chairman of the DSM Managing Board, commented: “Our positive momentum from Q1 continued and we are pleased to deliver another strong quarter. This was driven by good growth across our businesses and steady progress in our operations. Furthermore, we remain on track with our ambitious group-wide improvement and cost saving programs.

Materials performed particularly well, with good volume growth, notably in specialties, and a strong margin performance. This was supported by a favorable product mix, continued low input costs, and proactive margin management. In Nutrition, animal nutrition delivered high growth, benefitting in part from a favorable prior year comparison. We were also pleased with the continued progress in human nutrition, which delivered solid growth in line with our medium-term plans to outgrow the market.

During the quarter, uncertainty and volatility within the global macro-economic environment increased. While this remains a concern, we expect that for 2016 we will deliver ahead of our medium-term goals, given the strong performance of our business, underpinned by our continued focus on our improvement programs.”

Outlook 2016 revised upward

DSM aims to deliver increased full-year EBITDA and ROCE in line with the targets set out in its Strategy 2018: Driving Profitable Growth. While global macro-economic developments remain a concern, DSM now expects to deliver full-year 2016 results ahead of the medium term targets set out in its Strategy 2018, with an EBITDA growth for the year moving from high-single digit into the low to mid teens, and an increase in ROCE from high double-digit to over 200 basis points.

Key figures and indicators (cont’d)

in € million Q2 2016 Q2 2015 % change Volume Price/mix FX Other
Sales - Continuing Operations 1,913 1,886 1% 5% -3% -2% 1%
Nutrition 1,250 1,199 4% 7% -1% -4% 2%
Materials 600 632 -5% 1% -6% 0%  
Innovation Center 43 36 19% 19% 0% 0%  
Corporate Activities 20 19          
Discontinued Operations 0 506          
in € million H1 2016 H1 2015 % change Volume Price/mix FX Other
Sales - Continuing Operations 3,907 3,851 1% 6% -2% -3% 0%
Nutrition 2,545 2,446 4% 6% 1% -4% 1%
Materials 1,240 1,296 -4% 3% -6% -1%  
Innovation Center 83 73 14% 14% 0% -1% 1%
Corporate Activities 39 36          
Discontinued Operations 0 1,056          
in € million Q2 2016 Q2 2015 % change H1 2016 H1 2015 % change
Sales - Continuing Operations 1,994 1,965 1% 3,907 3,851 1%
Nutrition 1,295 1,247 4% 2,545 2,446 4%
Materials 640 664 -4% 1,240 1,296 -4%
Innovation Center 40 37 8% 83 73 14%
Corporate Activities 19 17   39 36  
Discontinued Operations 0 550   0 1,056  
EBITDA - Continuing Operations 328 279 18% 624 527 18%
Nutrition 237 208 14% 462 403 15%
Materials 117 106 10% 212 192 10%
Innovation Center 0 -3   1 -8  
Corporate Activities -26 -32   -51 -60  
Discontinued Operations 0 53   0 91  
EBITDA margin - Continuing Operations 16.4% 14.2%   16.0% 13.7%  
EBIT - Continuing Operations 211 157 34% 396 288 38%
Capital Employed - Continuing Operations1       7,616 7,897  
Average Capital Employed1       7,542 7,824  
ROCE - Continuing Operations (%)2       10.5% 7.4%  
Profit for the period, before exceptional items - Continuing Operations 135 110 23% 244 179 36%
Profit for the period, after exceptional items - Total DSM 135 101   220 30  
Net EPS before exceptional items - Continuing Operations 0.76 0.63 21% 1.36 1.02 33%
Net EPS after exceptional items - Total DSM 0.76 0.56   1.22 0.14  
Cash Flow - Continuing Operations 182 103   319 187  
Capital Expenditures - Continuing Operations3 78 107   177 208  
Net debt1       2,466 2,3214  

1) Before reclassification to held for sale
2) ROCE calculated based on weighted average capital employed
3) Cash, net of customer funding
4) Year-end 2015

In this report:
‘Organic sales growth’ is the total impact of volume and price/mix;
‘Discontinued operations’ comprises net sales and operating profit (before depreciation and amortization) of DSM Fibre Intermediates and DSM Composite Resins up to and including 31 July 2015;
‘Total Working Capital’ refers to the total of ‘Operating Working Capital’ and ‘non-Operating Working Capital’.

Update on strategy 2018: Driving Profitable Growth

DSM’s Strategy 2018: Driving Profitable Growth is focused on ensuring that the potential of the business portfolio that has been created translates into improved financial results. Reflecting its disciplined focus on performance, DSM has implemented a three-year strategic period with two headline financial targets: high single-digit annual EBITDA growth and high double-digit basis point annual ROCE growth.

To achieve these targets, DSM has defined clear actions, including outpacing market growth, cost reduction and efficiency improvement programs which will deliver €250-300 million versus the 2014 baseline, and furthermore aims to drive consistent improvements in capital efficiency.

Outpacing market growth

DSM is confident that it has the right business strategies in place to meet the needs of its customers and succeed in its markets, providing innovative and sustainable solutions. It intends to accelerate growth and outpace market growth in its key segments.

In Nutrition, DSM has a unique business model combining highly competitive, world-scale production capabilities for its key global products with customized local solution capabilities to meet segment and customer-specific needs. It has clear strategies to drive both top and bottom-line growth across its Nutrition business, leveraging its innovation power, improved segmentation capabilities and driving customer intimacy:

  • DSM’s Nutrition business is expanding in new segments and regions. DSM’s investment in a new omega-3 concentration facility in Canada (Mulgrave, Nova Scotia) enables the company to launch a new line of high-concentrate DHA and EPA, containing up to 85% omega-3, to support cardiovascular and cognitive health for human nutrition applications. DSM is currently also expanding its fast-growing i-health consumer line of products outside of the United States.
  • Furthermore, DSM develops new business models to increase market share, such as the implementation of a business to farmer (B2F) approach for swine and poultry in China, which is progressing well.
  • DSM is broadening and deepening its nutrition portfolio with new products and solutions. In H1 2016, DSM delivered strong growth in eubiotics for antibiotic-free poultry. This trend is gaining traction as consumers are increasingly avoiding protein products produced with growth-promoting antibiotics.
  • DSM continues to strengthen its core in Nutrition. In H1 2016, DSM opened a new production facility for vitamin B6 in China, utilizing an advanced technology platform, which enables lower production costs as well a reduction in environmental footprint. DSM also announced the expansion of its gellan gum and pectin production facilities in China.

In Materials, DSM is benefitting from the successful shift in the focus of its portfolio towards specialties, driven by the substitution of traditional materials for the more innovative, sustainable and higher-value alternatives that the company provides. In H1 2016, this quality shift was reflected in the progress of the EBITDA margin in the cluster. DSM’s strategy in Materials is to apply differentiated approaches to its portfolio of businesses, focusing on well-defined higher-growth segments, while maximizing returns in polyamide 6 polymer and powder coating resins.

DSM has a growth strategy for its specialty resins, engineering plastic compounds as well as solutions for life protection. For DSM’s high-performance plastics, functional materials, advanced surfaces, biomedical materials and high performance fiber solutions, DSM has defined an accelerated growth strategy.

  • One example of a new, sustainable solution contributing to accelerated growth is the application of DSM’s high-performance engineering plastics Stanyl®, ForTii® and ForTii® Eco in new ultra-thin USB Type-C connectors, the new industry standard.
  • DSM further drives accelerated growth by entering promising new segments, for example in Dyneema’s fiber solutions, which continue to grow in ultra-strong and lightweight high-performance apparel. In this year’s Tour de France, Team Giant-Alpecin’s riders wore cycling shorts and jerseys incorporating Dyneema® fiber to provide them with increased protection in the event of a fall.
  • In Resins & Functional Materials, DSM is making good progress with its sustainable waterborne coatings business for marine containers, a segment which is growing fast in China. Another promising example is the new Niaga® technology for fully recyclable carpets.

Cost reduction and efficiency improvement programs

In addition to its growth initiatives, DSM is rigorously executing its ambitious cost reduction and efficiency improvement programs across the company. All of these well-identified programs are on track with the milestones set for 2016. The plans are on track to reach the overall savings of €250 - €300 million by 2018 versus the 2014 baseline.

Global organizational and operational adjustments

DSM is well on track with the adjustments to its global organizational and operating model to support the company's growth and create a more agile, commercially-focused and cost-efficient business. Programs to globally leverage the company’s support functions are well underway, with new operating models, announced changes in staffing and clear milestones to drive the process. Continuous efforts are being made through change and culture initiatives to foster adoption of the right mindset and behaviors and thus embed the new way of working throughout the organization.

Stepping up sustainability aspirations

For DSM, sustainability is a core value as well as an important business driver. DSM is focused on delivering science-based, sustainable and scalable solutions that help address the challenges our world faces today. Not only do these products and solutions offer higher growth rates and better margins, DSM’s continuous endeavor for sustainability also provides the company with a focus area to reduce operating costs by decreasing its environmental footprint.

DSM has successfully embedded sustainability across its business activities and has formulated targets to improve the proportion of Brighter Living Solutions (formerly referred to as ECO+ and People+) to 65% of sales by 2020 and aims to reduce its (relative) emissions by 45% by 2025, compared to the reference year 2008. By 30 June 2016, Brighter Living Solutions amounted to 61% of sales, whilst relative greenhouse gas emissions had been reduced by 23% compared to 2008.

DSM has identified three key focus areas in sustainability, based on identified global societal trends that are affecting people, economies and markets, largely driven by demographic change: Nutrition, Climate Change and Circular Economy.

In Nutrition, DSM has unique expertise to develop products that can positively impact global nutrition, health and development, helping to achieve the UN Sustainable Development Goal’s target of ending all forms of malnutrition by 2030. DSM strives to make nutrition aspirational, affordable and available by working in partnership with cross-sector partners including the UN World Food Program. DSM and WFP’s partnership reached more than 28 million beneficiaries in 2015.

DSM believes that effectively tackling climate change is both a responsibility and a business opportunity. The company focuses on reducing its own carbon footprint, enabling the low-carbon economy with products and solutions and advocating climate action. During the second quarter DSM CEO Feike Sijbesma was named co-chair of the Carbon Pricing Leadership Coalition, which was launched by the World Bank and International Monetary Fund in 2015. The coalition is a voluntary partnerships of national and sub-national governments, businesses, and civil society organizations that agree to advance the carbon pricing agenda by working with each other towards the long-term objective of a carbon price applied throughout the global economy.

In the Circular Economy, DSM is dedicated to securing the future availability of natural resources, and unlocking more value from the limited resources that are available, by reducing resource use in its manufacturing processes, replacing scarce and toxic resources, extending the durability of products and materials, and recovering materials after first use, such as through DSM’s Niaga recyclable carpet technology.

Extracting value from partnerships

DSM has established partnerships for its former Pharma activities (DSM Sinochem Pharmaceuticals and Patheon) and for the remaining Bulk Chemical businesses (ChemicaInvest). These partnerships have been created with a view to ultimately exiting these businesses and DSM expects to extract significant value from them in the coming years.

DSM Sinochem Pharmaceuticals is developing well and continues to build its leadership position in sustainable antibiotics.

During Q2, ChemicaInvest’s caprolactam business undertook further steps to improve its competitive position on the global market, announcing a gradual wind down of its caprolactam plant in the US over the next sixteen months with no material adverse effect expected on DSM’s Engineering Plastics business in North America, as caprolactam supply has been secured.

At the end of July, in connection with the Initial Public Offering by Patheon N.V., DSM successfully completed the sale of 4.8 million ordinary shares in Patheon N.V. Following this transaction, DSM now holds approximately 48.7 million ordinary shares, or approximately 34% of Patheon N.V., with approximately 43% held by affiliates of JLL Partners and Patheon N.V.’s management team and 23% free float. Total cash proceeds from this transaction for DSM are expected to amount to approximately $240 million, consisting of net proceeds of around $95 million from the secondary offering and an expected $145 million in dividend distributions and capital repayments related to the IPO. DSM expects to realize a book profit of approximately €220 million, which will be reported as part of DSM’s Q3 2016 results, while any potential future gains on disposal of the remaining shares held in Patheon N.V., if any, will be recognized at the time of any such transaction(s). Patheon N.V. did not receive any proceeds from the sale of ordinary shares by DSM.

DSM also holds a 25% share (with a book value of approximately €30 million) in the Banner Life Sciences pharma business, which was spun off to Patheon’s investors in 2015. DSM will also look to monetize this shareholding over time. Banner Life Sciences is a specialty pharmaceutical company engaged in research and development for new drug formulations.


in € million Q2 2016 Q2 2015 % change H1 2016 H1 2015 % change
Sales 1,295 1,247 4% 2,545 2,446 4%
237 208 14% 462 403 15%
EBITDA margin (%) 18.3% 16.7%   18.2% 16.5%  
165 137 20% 326 266 23%
Capital Employed       5,391 5,474  
Average Capital Employed       5,317 5,339  
ROCE (%)       12.3% 10.0%  
Total Working Capital
      1,470 1,426  
Total Working Capital as % of Sales1       28.4% 28.6%  

1) Annualized last quarter sales

Q2 2016 sales were up 4% compared to Q2 2015. Organic sales growth at Nutrition was 9%, driven by 7% volume growth and 2% higher prices.

Volume growth was healthy in human nutrition and strong in animal nutrition, which partly benefitted from the comparison with Q2 last year.

Price/mix was up 2%. This was a result of price increases being implemented in all product categories, mainly in Latin America, together with slightly higher prices on average for premixes and vitamins when compared with Q2 2015.

Exchange rates had a 5% negative impact on sales, mainly due to the effect of the Brazilian real and a weaker US dollar.

Q2 2016 EBITDA was €237 million, up 14% compared to Q2 2015, driven by strong organic growth and the effects of the improvement and savings programs. All businesses contributed to this improvement in results. Although currencies had a clear negative impact on sales, the impact on EBITDA was limited as the Swiss franc weakened somewhat against the euro in comparison with the same period last year.

Q2 2016 EBITDA margin was 18.3% compared to 16.7% in the same period last year and 18.0% in Q1 2016, reflecting the good organic growth, supported by the progress made on the improvement programs.

Animal Nutrition & Health

Sales development

Q2 2016 sales in animal nutrition showed 14% organic growth including 10% volume growth and 4% improvement in price/mix compared to Q2 2015.

This growth in the year-on-year comparison was helped by a one-off effect in the comparative quarter of 2015, when animal nutrition was impacted by a key raw material supply interruption at Tortuga due to a fire in the port of Santos (Brazil). This led to lost sales of €15-20 million in Q2 2015. Adjusting for this effect, volume growth would have been 6-7%. Volumes were strong in vitamins, premixes and eubiotics.

Markets in North America, Asia and Europe were strong, while Latin America remained weak.

Overall, prices showed a 4% increase versus the same period last year. Part of this increase related to the implementation of price increases in local currencies in Latin America while list-prices are in US dollars. As a result, margin levels as reported in euros were protected during the quarter. Besides this, prices for vitamins were slightly up overall versus the same quarter a year ago, with some of the B-vitamins showing an increase. Contract prices for vitamin E were however still slightly below the average of Q2 2015, despite clear increases in spot prices during Q2 2016.

Human Nutrition & Health

Sales development

Q2 2016 organic sales in human nutrition grew by 4% compared to Q2 2015, predominantly driven by higher volumes (+3%). Prices were slightly up across the board when compared to Q2 2015, while currencies had a negative impact, mainly due to a somewhat weaker US dollar.

  • Food & beverage performed well overall, with sales in the US improving.
  • Dietary Supplements markets outside North America performed well. Markets for multi-vitamins in North America remained weak, however higher retail-ready solutions sales in Q2 2016 enabled DSM to maintain stable sales versus the previous year. Fish oil-based omega-3 sales were down in line with the market. DSM’s consumer business i-Health continued its strong double digit growth trajectory and made preparations during the quarter for further marketing efforts in the second half of the year.
  • Infant Nutrition performed well, with stable growth in a healthy market.

Food Specialties

The Food Specialties businesses delivered 3% organic growth in the second quarter of 2016, driven by growth in food enzymes and hydrocolloids.


in € million Q2 2016 Q2 2015 % change H1 2016 H1 2015 % change
Sales 640 664 -4% 1,240 1,296 -4%
117 106 10% 212 192 10%
EBITDA margin (%) 18.3% 16.0%   17.1% 14.8%  
86 74 16% 148 127 17%
Capital Employed       1,775 1,897  
Average Capital Employed       1,751 1,857  
ROCE (%)       16.9% 13.6%  
Total Working Capital
      312 418  
Total Working Capital as % of Sales1       12.2% 15.7%  

1) Annualized last quarter sales

Sales development

Q2 2016 sales were 4% below Q2 2015 mainly as a result of 7% lower prices, fully reflecting lower input costs. Overall, volumes were up by 5%, outperforming market growth. Strong growth in the specialty segments more than compensated for lower volumes in polyamide 6 polymers.

  • DSM Engineering Plastics: Volumes were down slightly in Q2 versus the previous year due to lower polyamide 6 polymer volumes, mainly as a result of a maintenance stop in the Netherlands. Volume developments in the higher-value specialties portfolio were favorable. Automotive was strong in Europe. On a regional basis, the US and Asia performed well and Europe was strong. Prices were lower reflecting lower input costs, notably in polyamide 6.
  • DSM Resins and Functional Materials: Volumes were up significantly in all product segments compared to Q2 2015. Europe benefitted from improving conditions in the building & construction markets. Specialty resins showed strong growth driven by healthy demand for waterborne resins in China – evidence of the increasing environmental awareness in China – as well as by strong sales in the US. Functional Materials delivered favorable growth, both in fiber-optic materials as well as in materials for 3D printing. Overall, the business clearly outperformed market growth in Q2 2016. Prices were lower reflecting lower input costs.
  • DSM Dyneema: Sales development was flat, with good growth in life protection, mainly for personal protection applications, offset by commercial marine, where conditions in the oil-related off-shore market remained weak.

Q2 2016 EBITDA increased by 10% compared with Q2 2015 as a result of strong growth in the specialty segments, lower input costs, the benefits of the efficiency and cost saving programs carried out over recent years, and good margin management.

Q2 2016 EBITDA margin was high at 18.3%, up from 16.0% in Q2 2015, reflecting a higher proportion of specialties in the product mix, current low input costs, and the benefits from cost savings and efficiency improvements.

Innovation center

in € million Q2 2016 Q2 2015 % change H1 2016 H1 2015 % change
Sales 40 37 8% 83 73 14%
0 -3   1 -8  
-5 -10   -10 -22  
Capital Employed       559 564  

Q2 2016 sales were 8% above Q2 2015, with the increase fully driven by higher volumes. DSM Biomedical delivered a good performance. DSM Advanced Surfaces achieved strong growth in its innovative anti-reflective coatings for solar panels.

Q2 2016 EBITDA was €3 million higher when compared to the same period last year, reaching break-even. This improvement was driven by higher sales, more focused innovation activities and cost savings.

Corporate Activities

in € million Q2 2016 Q2 2015 H1 2016 H1 2015
Sales 19 17 39 36
-26 -32 -51 -60
-35 -44 -68 -83

Q2 2016 EBITDA was €6 million better than in Q2 2015, when EBITDA was impacted by the insurance costs related to the Tortuga supply interruption.

Key Joint Ventures and Associates

in € million Q2 2016 Q2 2015 % change H1 2016 H1 2015 % change
DSM Sinochem Pharmaceuticals
Sales 114 112 2% 226 229 -1%
EBITDA% 14% 16%   15% 14%  
Sales 415 397 5% 791 774 2%
EBITDA% 19% 20%   17% 19%  
Sales 437 n.a. n.a. 892 n.a. n.a.
EBITDA% 0%     2%    

1) Patheon (formely reported as DPx Holding) respective periods are for the 2nd quarter from 1 February - 30 April and for YTD from 1 November - 30 April"

  • DSM Sinochem Pharmaceuticals (50% DSM) delivered solid results driven by a favorable product and geographical mix.
  • Patheon (49% DSM) delivered solid results. Patheon completed its Initial Public Offering of ordinary shares on 27 July (see page 6 of this press release for more information). DSM’s shareholding in Patheon will be approximately 34% as of Q3.
  • ChemicaInvest (35% DSM) posted lower Q2 results due to weakness in caprolactam.

Financial Overview

Exceptional Items

Exceptional items in the second quarter amounted to +€4 million (+€6 million after tax). A profit of €17 million was included with regard to the release of an acquisition-related liability, partly offset by -€13 million related to restructuring costs.

Net profit (continuing operations)

in € million Q2 2016 Q2 2015 H1 2016 H1 2015
EBIT 211 157 396 288
Financial Income & Expense -29 -35 -66 -87
Income Tax -34 -23 -61 -37
Effective Tax Rate (%)     18.5% 18.0%
Share of profit of associates/ Joint control entities -13 11 -25 15
Non-controlling interest -1 1 -2 3
Net Profit from Continuing Operations (before exceptional items)1 134 111 242 182
Net Earnings per ordinary share - Continuing Operations, before exceptional items (€) 0.76 0.63 1.36 1.02

1) Net profit of continuing operations attributable to equity holders of Koninklijke DSM N.V.

Financial income and expense amounted to -€29 million in Q2 2016 compared to -€35 million in Q2 2015, mainly as a result of lower interest expenses and more favorable hedge results.

DSM’s share of profit of associates/joint control entities before exceptional items decreased in Q2 2016 to a loss of €13 million versus a profit of €11 million in Q2 2015. The net result of Patheon (49%) decreased by €16 million following the leveraged dividend pay-out, the divestment of the ESIM business and the spin-off of Banner Life Sciences. The net result of ChemicaInvest (35%) amounted to a loss of €7 million following adverse market conditions in caprolactam.

Cash Flow, Capital Expenditures and Financing

in € million Q2 2016 Q2 2015 H1 2016 H1 2015
Cash from Operating Activities - Continuing Operations 182 103 319 187
Total Working Capital - Continuing Operations     1,481 1,571
Total Working Capital as % of Sales - Continuing Operations     18.6% 20.0%
Capital Expenditure (cash, net of customer funding) - Continuing Operations 78 107 177 208
Net Debt     2,466 2,3211

1) Year-end 2015

Cash flow from operating activities amounted to €182 million showing an improvement of €79 million compared to Q2 2015.

Total Working Capital amounted to €1,481 million at the end of Q2 2016 compared to €1,571 million at the end of Q2 2015, which represents 18.6% as a percentage of annualized Q2 sales (Q2 2015: 20.0%).

Net debt increased by €145 million compared to the end of 2015 and stood at €2,466 million. The increase was mainly due to the payment of dividend and the repurchase of shares, covering existing option plans and stock dividends.

Interim dividend

DSM will pay an interim dividend of €0.55 per ordinary share for 2016. As usual, this represents one third of the total dividend paid for the previous year. The interim dividend should not be taken as an indication of the total dividend for the year 2016. The interim dividend will be payable in cash or in the form of ordinary shares at the option of the shareholder, with a maximum of 40% of the total dividend amount available for stock dividend. If more than 40% of the total dividend is requested by the shareholders to be paid out in shares, those shareholders who have chosen to receive their dividend in shares will receive their stock dividend on a pro rata basis, the remainder being paid out in cash. Dividend in cash will be paid after deduction of 15% Dutch dividend withholding tax. The ex-dividend date is 4 August 2016. The interim dividend will be payable as from 25 August 2016.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420

Dave Huizing

Vice President Investor Relations
+31 45 578 2864

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864

This site uses cookies to optimize your user experience.

Read more